Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Active not recruiting × Bevacizumab × Clear all

Phase

Phase 2 52 Phase 3 32 Phase 1 18 Phase 1/2 15 Phase 2/3 5 Phase NA 3 Phase EARLY_PHASE1 3 Phase 4 1

Status

Completed 14 Recruiting 5 Terminated 4 Withdrawn 2 Unknown 2 Not yet recruiting 2 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

Human Papillomavirus Recombinant Vaccine nonavalent 5 Dexamethasone 4 Cisplatin 3 lorlatinib 2 human papillomavirus vaccine, L1 type 16, 18 2 adacel 2 Tobacco Use Cessation Devices 2 Tetanus Toxoid 2 Prednisone 2 Papillomavirus Vaccines 2 Letrozole 2 Lenalidomide 2 Diphtheria-Tetanus-acellular Pertussis Vaccines 2 Diphtheria Toxoid 2 Denosumab 2 Carboplatin 2 Cannabidiol 2 Atorvastatin 2 Anesthesia, Epidural 2 xiapex 1 venetoclax 1 trametinib 1 tirbanibulin 1 tenofovir alafenamide 1 sofosbuvir-velpatasvir drug combination 1 ruxolitinib 1 ribociclib 1 rasburicase 1 radium Ra 223 dichloride 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06121401 2025-09-17

IOLANTHE

Mario Negri Institute for Pharmacological Research

Phase 4 Active not recruiting

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡